- Home
- CDNL vs INBX Comparison
CDNL vs INBX Comparison
Compare CDNL & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CDNL | INBX |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.9M | 999.7M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | CDNL | INBX |
|---|---|---|
| Price | $48.96 | $102.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $38.00 | ★ $150.00 |
| AVG Volume (30 Days) | 426.7K | ★ 489.3K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $50.30 | N/A |
| Revenue Next Year | $8.41 | N/A |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $21.98 | $12.80 |
| 52 Week High | $63.18 | $155.29 |
Technical Indicators
Market Signals| Indicator | CDNL | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 47.94 | 45.50 |
| Support Level | $45.52 | $99.20 |
| Resistance Level | $54.55 | $153.14 |
| Average True Range (ATR) | 4.67 | 13.75 |
| MACD | -1.11 | -3.93 |
| Stochastic Oscillator | 9.23 | 8.06 |
Price Performance
Historical ComparisonAbout CDNL Cardinal Infrastructure Group Inc. Class A Common Stock
Cardinal Infrastructure Group Inc provides a comprehensive suite of infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. Its operations leverage a large highly skilled workforce and a fleet of specialized equipment to deliver wet utility installations (water, sewer, and stormwater systems), as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.